Palo Alto, CA, United States of America

Philip Christopher Evard

This inventor holds 46 USPTO granted patents and 4 published patent applications and 1 EPO patent, primarily in Cardiovascular Catheters. Top assignees: Medtronic Vascular, Inc., Heartport, Inc., Transvascular, Inc.. Active years: 1991-2020.

USPTO Granted Patents = 46 

% Patents Active = 67.4


Average Co-Inventor Count = 4.8

ph-index = 39

Forward Citations = 13,420(Granted Patents)


Location History:

  • Los Altos, CA (US) (2015 - 2018)
  • Palo Alto, CA (US) (1991 - 2020)

Company Filing History:


Years Active: 1991-2020

Loading Chart...
Loading Chart...
Areas of Expertise:
Cardiovascular
Catheters
Drug Delivery
Tissue Penetration
Bypass Methods
Imaging Transducers
Arterio-Venous Bypass
Flow Blocking
Percutaneous Procedures
Anatomical Structures
Coronary Vasculature
Cardioplegia
46 patents (USPTO):Explore Patents

Title: The Innovative Mind of Philip Christopher Evard

Introduction: Philip Christopher Evard is a renowned inventor based in Palo Alto, CA, known for his groundbreaking contributions to various industries.

Latest Patents: Philip Christopher Evard holds several patents in the fields of technology, healthcare, and sustainable energy, with his most recent patent focusing on a revolutionary method for renewable energy storage.

Career Highlights: Throughout his illustrious career, Philip Christopher Evard has been recognized for his innovative solutions to complex problems, earning him prestigious awards and accolades in the inventor community.

Collaborations: Philip Christopher Evard has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life, showcasing his ability to work across diverse teams and disciplines.

Conclusion: Philip Christopher Evard's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…